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ABSTRACT
Introduction: Gout affects 2.5% of the UK’s adult
population and is now the most common type of
inflammatory arthritis. The long-term management of
gout requires reduction of serum urate levels and this
is most often achieved with use of xanthine oxidase
inhibitors, such as allopurinol. Febuxostat is the first
new xanthine oxidase inhibitor since allopurinol and
was licensed for use in 2008. The European Medicines
Agency requested a postlicensing cardiovascular safety
study of febuxostat versus allopurinol, which has been
named the Febuxostat versus Allopurinol Streamlined
trial (FAST).
Methods and analysis: FAST is a cardiovascular
safety study using the prospective, randomised, open,
blinded endpoint design. FAST is recruiting in the UK
and Denmark. Recruited patients are aged over
60 years, prescribed allopurinol for symptomatic
hyperuricaemia and have at least one additional
cardiovascular risk factor. After an allopurinol lead-in
phase where the dose of allopurinol is optimised to
achieve European League against Rheumatism (EULAR)
urate targets (serum urate <357 µmol/L), patients are
randomised to either continue optimal dose allopurinol
or to use febuxostat. Patients are followed-up for an
average of 3 years. The primary endpoint is first
occurrence of the Anti-Platelet Trialists’ Collaboration
(APTC) cardiovascular endpoint of non-fatal myocardial
infarction, non-fatal stroke or cardiovascular death.
Secondary endpoints are all cause mortality and
hospitalisations for heart failure, unstable, new or
worsening angina, coronary or cerebral
revascularisation, transient ischaemic attack, non-fatal
cardiac arrest, venous and peripheral arterial vascular
thrombotic event and arrhythmia with no evidence of
ischaemia. The primary analysis is a non-inferiority
analysis with a non-inferiority upper limit for the HR for
the primary outcome of 1.3.
Ethics and dissemination: FAST (ISRCTN72443728)
has ethical approval in the UK and Denmark, and results
will be published in a peer reviewed journal.
Trial Registration number: FAST is registered in the
EU Clinical Trials Register (EUDRACT No: 2011-001883-
23) and International Standard Randomised Controlled
Trial Number Register (ISRCTN No: ISRCTN72443728).
INTRODUCTION
Gout is the commonest inﬂammatory arthro-
pathy in men over the age of 40, and current
prevalence is estimated at 1–2% of the adult
population in western countries with UK
prevalence of 2.5%.1–4 Gout is characterised
by the deposition of monosodium urate
Strengths and limitations of this study
▪ Use of technology including an electronic case
report form, web portal and record linkage to
identify potential endpoints provides efficient
data management.
▪ The open-label design provides good external
validity as the trial is conducted in the normal
care setting. The endpoint committee is blinded
to randomised treatment.
▪ A minor study limitation will be the non-
inclusion of younger populations with
hyperuricaemia.
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crystals in joints and other tissues, causing an acutely
painful inﬂammatory arthritis that can progress to a
chronic and disabling destructive arthropathy. Crystal
deposition in soft tissues may also be seen as gouty
tophi. Although serum urate levels correlate poorly with
disease activity, hyperuricaemia is the most signiﬁcant
risk factor for the development of symptomatic gout.
Hyperuricaemia is generally deﬁned as urate above
approximately 400 µmol/L (6.8 mg/dL), as this is the
concentration at which uric acid becomes insoluble in
plasma.5
It is well recognised that patients with gout have
increased cardiovascular morbidity and mortality com-
pared with the general population, and urate levels are
increasingly believed to be an independent predictor of
cardiovascular mortality. Theories as to the speciﬁc
causal relationship between hyperuricaemia and cardio-
vascular disease/mortality vary; however, the correlation
between the two is widely recognised. It is also not clear
whether lowering urate levels would improve the cardio-
vascular event rate of patients with hyperuricaemia.6–9
Management of gout was revolutionised in the 1960s
with the introduction of allopurinol, the ﬁrst xanthine
oxidase inhibitor, which reliably reduced urate levels,
gout ﬂares and long-term complications of gout.10 The
current European League against Rheumatism
(EULAR) guideline for the management of gout recom-
mends that urate lowering therapy (ULT) is indicated in
patients with recurrent acute ﬂares, arthropathy, tophi
or radiographic changes of gout. The therapeutic goal
of ULT is to promote crystal dissolution and prevent
crystal formation. This is achieved by maintaining the
serum urate level (SUA) below the saturation point for
monosodium urate, and the target level recommended
is <357 µmol/L (<6 mg/dL).11 Allopurinol is currently
the ﬁrst-line ULT in the UK and Europe. It is licensed in
the dose range of 100–900 mg; however, patients with
renal impairment are recommended to take the
minimum effective dose required to achieve urate
control.12 In the UK, the majority of patients are pre-
scribed between 100 and 300 mg of allopurinol daily,
and primary care surveys have shown that the EULAR
guideline target for urate is achieved in less than 50% of
patients with gout receiving 300 mg of allopurinol.13
Febuxostat is a novel xanthine oxidase inhibitor which
was licensed in 2008 for the treatment of chronic hyper-
uricaemia in conditions where urate deposition has
occurred. The febuxostat Phase III randomised con-
trolled trials demonstrated that 80 mg febuxostat was
superior to allopurinol 300 mg in achieving and main-
taining the target urate level of <357 µmol/L.14
Febuxostat can also be prescribed to patients with
mild-to-moderate renal insufﬁciency without the need
for dose adjustment, and therefore provides an import-
ant alternative in the treatment of hyperuricaemia in
patients with gout with renal impairment.
In the Phase III and long-term clinical extension
studies of febuxostat, there was a numerical increase in
investigator-reported cardiovascular events with febuxo-
stat when compared to allopurinol. However, no statistic-
ally signiﬁcant differences were found, no causal
relationship was established and 60% of the patients in
these trials had ≥2 risk factors for cardiovascular disease.
The European Union Risk Management Plan for
febuxostat (V.2.0; 19 February 2008) indicated that a
postmarketing study to evaluate cardiovascular safety of
febuxostat was to be conducted as part of the febuxostat
pharmacovigilance plan. To fulﬁl this postlicensing obli-
gation, a large safety study of febuxostat versus standard
ULT with allopurinol for patients with symptomatic
hyperuricaemia (gout) is being undertaken. The study is
named the FAST.
METHODS
Trial design
Overall trial design
FAST is a prospective, randomised, open-label, blinded
endpoint evaluation (PROBE) design trial to compare
the cardiovascular safety of febuxostat and allopurinol.
The PROBE design allows the real-world use of the two
drugs to be compared, and also allows for dose adjust-
ments during the study, if required.15 Recruited patients
are randomised to either allopurinol or febuxostat and
followed-up for a minimum of 3 years.
Study population
FAST has study centres in Scotland, England and
Denmark. Each centre identiﬁes regional general prac-
tices to act as study sites and potential study patients are
recruited from these study sites. General practice patient
lists are searched for patients aged 60 years or more who
are taking chronic allopurinol (deﬁned as 60 days or 2
or more prescriptions for allopurinol in the last
6 months). Patients meeting these selection criteria have
their case records reviewed by appropriately trained staff
to determine eligibility according to inclusion and exclu-
sion criteria (detailed in boxes 1 and 2). Patients identi-
ﬁed as potentially suitable are provided with written
study information and invited to attend a screening visit.
Consent
Written, informed consent is obtained at the screening
visit for all patients who wish to proceed in the study.
Screening visits are conducted by research nurses with
appropriate training in obtaining informed consent.
Randomisation
Randomisation is performed through a central web-
based randomisation facility located at the Robertson
Centre for Biostatistics, University of Glasgow.
Randomisation is stratiﬁed according to previous cardio-
vascular events (myocardial infarction (MI), stroke or
hospitalisation for congestive heart failure or peripheral
vascular disease).
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Data storage—electronic clinical report form
Patient data are entered via a secure web-based elec-
tronic clinical report form (eCRF) with a central data-
base at the Robertson Centre for Biostatistics, University
of Glasgow.
Trial treatments
Trial treatments are allopurinol or febuxostat.
Allopurinol dose is determined during the allopurinol
lead-in phase (see below) and febuxostat is started at
80 mg daily with potential to increase to 120 mg daily if
SUA is above the EULAR target at a 2 week check. The
allopurinol lead-in phase is required because febuxostat
80 mg is a more potent urate lowering therapy than low
dose allopurinol. A study overview is shown in ﬁgure 1.
Trial medication is supplied directly to each patient by
post from the Dundee University Research Pharmacy. All
trial medication is supplied open-label.
Allopurinol lead-in phase
An allopurinol lead-in phase precedes randomisation. If
the SUA exceeds the EULAR recommended target of
<357 µmol/L on screening blood tests, the daily allopur-
inol dose is increased by 100 mg. SUA levels are
rechecked after 2 weeks on the higher dose and this
process is repeated until the EULAR target is achieved
or the maximum tolerated dose of allopurinol is
reached. If SUA at screening is <357 µmol/L then no
dose titrations are required and the patient proceeds
straight to randomisation. Patients with renal impair-
ment (estimated-glomerular ﬁltration rate 30–60 mL/
Box 2 FAST exclusion criteria
Exclusion criteria
1. Patients who have any contraindication to febuxostat or allo-
purinol (with reference to the summary of product character-
istics) or any of the components of their formulations.
2. Patients who are not receiving allopurinol as urate lowering
therapy.
3. Patients with severe renal impairment (estimated-glomerular
filtration rate <30 mL/min as defined by the Cockroft-Gault
formula (http://www.nephron.com/cgi-bin/CGSI.cgi) accord-
ing to creatinine, age, sex and body weight).
4. Patients with moderate or severe hepatic impairment, that is,
cirrhosis with clinical and/or biological decompensation (ie,
alanine aminotransferase or aspartate aminotransferase >3×
reference value, ascites, lower limb oedema, icterus or
increased prothrombin time >2× reference value).
5. Patients with a life-threatening comorbidity or with a signifi-
cant medical condition and/or conditions that would interfere
with the treatment, safety or compliance with the protocol.
6. Patients with a diagnosis of, or receiving treatment for,
malignancy (excluding minor skin cancer) in the previous
5 years.
7. Patients who have experienced either a myocardial infarction
or stroke within the 6 months prior to the screening visit.
8. Patients with congestive heart failure, New York Heart
Association (NYHA) Class III or IV.
9. Patients whose behaviour or lifestyle would render them less
likely to comply with study medication (ie, abuse of alcohol,
substance misuse, debilitating psychiatric conditions or
inability to provide informed consent).
10. Patients with a current acute gout flare or who are within
14 days of the resolution of a gout flare.
11. Patients currently participating in another clinical trial or who
have participated in a non-interventional clinical trial in the
previous 1 month or an interventional clinical trial in the pre-
vious 3 months.
Box 1 FAST inclusion criteria
Inclusion criteria
1. Male or female patients aged 60 years or older with at least
one additional cardiovascular risk factor:
▸ Age ≥70 years (male) or ≥75 years (female)
▸ Smoking (current or within the last 2 years)
▸ Diabetes mellitus
▸ Impaired glucose tolerance
▸ Hypertension (systolic blood pressure >140 mm Hg and/or
diastolic blood pressure >90 mm Hg) or receiving treat-
ment to lower blood pressure
▸ Dyslipidaemia (investigator assessment)
▸ Chronic kidney disease
▸ Microalbuminuria or proteinuria
▸ Family history of coronary heart disease or stroke in first-
degree relative at age <55 years
▸ Inflammatory arthritis (investigator assessment—including
rheumatoid arthritis, psoriatic arthritis, ankylosing
spondylitis)
▸ Chronic non-steroidal anti-inflammatory drugs therapy
(investigator assessment)
▸ Previous cardiovascular event (myocardial infarction, cere-
brovascular accident or transient ischaemic attack)
▸ Peripheral vascular disease (investigator/clinical
assessment)
▸ Chronic obstructive pulmonary disease
▸ Body mass index >30 kg/m2
2. Patients who, in the opinion of the recruiting physician,
require treatment for chronic hyperuricaemia where urate
deposition has already occurred (including a history or pres-
ence of tophus and/or gouty arthritis) fulfilling the recommen-
dation for treatment with urate lowering therapy.
3. Patients who have received ≥60 days treatment with allopur-
inol, or ≥2 allopurinol prescriptions, within the previous
6 months.
4. Patients, who in the opinion of the recruiting physician or
study site coordinator, are eligible for treatment (with refer-
ence to the summary of product characteristics) with either
allopurinol or febuxostat.
5. Patients who are willing to give permission for their paper and
electronic medical records, hospitalisation data, prescribing
data and (in the event of their death) their death certification
data to be accessed and abstracted by trial investigators.
6. Patients who are willing to be contacted and interviewed by
trial investigators or delegates (suitably trained research
nurses), should the need arise (eg, for adverse event assess-
ment and to determine whether an episode of acute gout has
occurred).
MacDonald TM, et al. BMJ Open 2014;4:e005354. doi:10.1136/bmjopen-2014-005354 3
Open Access
group.bmj.com on May 24, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
min) have their allopurinol dose titrated in exactly the
same manner as those without renal impairment. This
reﬂects published guidance on allopurinol titration in
renal impairment which recommends starting at a low
dose and titrating to achieve urate target.16
Allopurinol washout
Once patients are randomised and prior to start of ran-
domised treatment all patients have an allopurinol
washout period of at least 7 days (window 7–21 days).
Gout flare prophylaxis
Patients requiring up-titration of allopurinol during the
allopurinol lead-in phase and all patients postrandomisa-
tion are offered gout ﬂare prophylaxis. First-line prophy-
laxis is with colchicine (0.5 mg once or twice daily) and
second-line alternatives are non-steroidal anti-
inﬂammatory drugs (NSAID’s; naproxen, diclofenac or
meloxicam) with gastric protection. Prophylaxis postran-
domisation is offered for 6 months. Patients may decline
prophylaxis or discontinue prophylaxis at any time and
prophylaxis may be tailored by the patients’ primary
care physician, particularly if there are concerns with
long-term NSAID use. General practitioners (GPs) are
left to manage gout ﬂares according to local guidelines.
Postrandomisation treatment
Patients randomised to allopurinol continue to receive
allopurinol at the dose determined before randomisa-
tion (ie, the dose required to achieve SUA level
<357 µmol/L or the maximum tolerated dose). Patients
randomised to febuxostat will start with 80 mg daily with
potential to increase the dose to 120 mg if the SUA is
≥357 µmol/L after 2 weeks.
All drugs supplied to randomised patients from the
Dundee University Research Pharmacy are recorded on
the patient’s eCRF, providing a cumulative record of sup-
plied and returned medications.
Efficacy
If therapeutic efﬁcacy is judged to be inadequate, physi-
cians have the option to increase the dose of study medi-
cation according to their clinical judgment and EULAR
recommendations provided this remains in line with the
current summary of product characteristics for allopur-
inol and febuxostat. GPs are also free to decrease the
dose of either drug if appropriate. Changes in dose are
recorded in the eCRF.
Tolerability
Patients who experience any treatment-related adverse
events may have their dosage adjusted or trial medica-
tion stopped according to clinical judgment. Study per-
sonnel report such events as adverse reactions (with
severity assessment) as appropriate.
Follow-up
Patients will be followed-up for an average of 3 years
from randomisation. Contact will be made by study
nurses every 2 months by phone, letter or visit to the
patient. Every patient will be seen annually and annual
visits will include clinical review and annual blood
testing for SUA level, renal and liver function.
Recruiting physicians and the patients’ GP may also
report any signiﬁcant events and adverse events thought
to be related to study medication at any time during the
follow-up period.
Record linkage is available in Scotland, England and
Denmark and refers to the method by which patient-
speciﬁc information that is stored separately can be
linked to provide comprehensive patient data for hospi-
talisations and deaths.17 Record linkage will be per-
formed at regular intervals during FAST follow-up.
Trial endpoints
Primary endpoint
The primary endpoint is the ﬁrst occurrence after ran-
domisation of any event included in the Anti-Platelet
Trialists’ Collaboration (APTC) composite endpoint
(hospitalisation for non-fatal MI/biomarker positive
acute coronary syndrome, non-fatal stroke (whether
reported to have been hospitalised, non-hospitalised or
to have occurred during a hospitalisation) or death due
to a cardiovascular event).18
Secondary endpoints and further planned exploratory
analysis are detailed in box 3.
Assessment of endpoints, adverse events and serious
adverse events
All observed or volunteered adverse events that are con-
sidered to be either serious or related to study treatment
(or both) are recorded in the eCRF. Physicians assess
Figure 1 Overview of the FAST trial.
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the causality and expectedness of any event thought to
be related to one of the study medications. An event is
deemed serious if it results in death, is life-threatening,
requires hospitalisation, results in persistent or signiﬁ-
cant disability/incapacity or any other important
medical event that requires medical or surgical interven-
tion to prevent serious outcomes (whether or not the
event was related to study medication). Serious adverse
events (SAEs) are reported by study personnel without
delay and are also collected regularly where appropriate
using record-linkage methods. SAEs are followed up
until resolved or the patient has died. Events that are
neither serious nor related to study medication are not
required to be reported. Primary and secondary study
endpoints and their associated symptoms or laboratory
abnormalities are not reported as suspected unexpected
serious adverse reactions (SUSARs).
If a reported SAE is a potential study endpoint, more
detailed information is collected and an anonymised
endpoint package is prepared. Endpoint data are adjudi-
cated by an independent endpoint committee blinded
to randomised treatment.
DATA ANALYSIS AND STATISTICAL METHODS
Sample size
A total of 456 APTC events are required to show non-
inferiority between the febuxostat and allopurinol treat-
ment arms assuming non-inferiority limit for the HR
(febuxostat vs allopurinol) of 1.3, with 80% power and a
one-sided α of 0.025. Non-inferiority will be claimed if
the upper limit of the 95% CI for the HR is ≤1.3 for the
per-protocol analysis.
Assuming a cardiovascular event rate at 3 years in the
allopurinol treatment arm is estimated at 10%,i then
2282 patients will be required in each treatment arm to
detect the 456 events. Allowing for a loss of follow-up
due to non-cardiovascular death, withdrawal of consent
or other loss to follow-up, we intend to recruit an add-
itional 20% of patients to a total of 5706 patients with
2853 patients in each treatment arm.
Primary analysis
A full statistical plan is developed for the primary ana-
lysis. Time to event analysis will involve Cox proportional
hazards models including the randomised treatment
group and randomisation strata (previous cardiovascular
events (yes/no) as covariates). Statistical signiﬁcance for
effect will be based on the Wald statistic with associated
95% CIs for the estimated HR comparing febuxostat to
allopurinol.
The ﬁrst analysis to be carried out will be a non-
inferiority analysis of the primary outcome based on the
per-protocol population (those patients remaining on
randomised therapy) with a supporting non-inferiority
analysis based on the intention-to-treat (ITT) popula-
tion. Per-protocol analysis will exclude patients who dis-
continued trial therapy, deaths from non-cardiovascular
causes and patients lost to follow-up. If non-inferiority is
demonstrated, a superiority analysis will be carried out
based on the ITT population.
Sensitivity analysis
A sensitivity analysis will be performed by censoring
patient follow-up at 90 days beyond the per-protocol
period or end of study, whichever comes ﬁrst. This will
be performed for primary and secondary endpoints.
To adjust for the possibility of differential drop-out in
the per-protocol analysis, a further analysis will be
carried out adjusting for age, sex, LDL-cholesterol levels
and HDL-cholesterol levels, systolic blood pressure,
smoking status and histories of diabetes, hypertension
and cardiovascular disease.
ETHICS AND DISSEMINATION
Steering Committee and Independent Data Monitoring
Committee
A Steering Committee oversees the conduct of the trial.
An independent Data Monitoring Committee receives
unblinded data and has the power to recommend modi-
ﬁcations to the conduct of the study, including early
Box 3 FAST secondary and exploratory endpoints
Secondary endpoints
The following secondary endpoints (in rank order of import-
ance) will be evaluated using a time to event analysis:
▸ Hospitalisation for non-fatal myocardial infarction/biomarker
positive acute coronary syndrome
▸ Non-fatal stroke (whether reported to have been hospita-
lised, non-hospitalised or to have occurred during a
hospitalisation)
▸ Cardiovascular death
▸ All cause mortality
▸ Hospitalisation for heart failure
▸ Hospitalisation for unstable, new or worsening angina
▸ Hospitalisation for coronary revascularisation
▸ Hospitalisation for cerebral revascularisation
▸ Hospitalisation for transient ischaemic attack
▸ Hospitalisation for non-fatal cardiac arrest
▸ Hospitalisation for venous and peripheral arterial vascular
thrombotic event
▸ Hospitalisation for arrhythmia with no evidence of ischaemia
The following endpoints will be evaluated as an incidence
rate:
▸ Cardiovascular mortality
▸ Anti-Platelet Trialists’ Collaboration events in each treatment
arm
Exploratory efficacy endpoint
The proportion of patients whose urate level is ≥6.0, <6.0 and
<5.0 mg/dL after 1, 2 and 3 years of treatment.
iCardiovascular event rate was calculated using cohorts of patients from
the Tayside Medicines Monitoring Unit database who were dispensed
allopurinol in Scotland between 1994 and 2002 and cardiovascular
events and deaths occurring in these patients up to 2002 from the
Scottish Morbidity Record One and General Registrar Ofﬁce database.
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discontinuation based on a risk/beneﬁt assessment of
the study data.
Study sponsorship: monitoring, audit, quality control and
quality assurance
The study sponsor is the University of Dundee which
undertakes monitoring and quality assurance. The trial is
funded by Menarini in partnership with Ipsen and Tejin.
Access to data
The completed, original eCRF data will be the joint
property of the University of Dundee and the University
of Glasgow. Data will be available for authorised repre-
sentatives of the universities or regulatory authorities or
to third parties with express written permission from the
universities.
Ethics
FAST is registered as ISRCTN72443728. The trial is per-
formed in line with Good Clinical Practice guidelines and
International Society of Pharmacoepidemiology (ISPE)
Good Pharmacoepidemiology Practice guidance.19
Dissemination
The results of the trial will be published in a peer-
reviewed scientiﬁc journal and presented at a major
conference.
DISCUSSION
The trial design of FAST allows a large safety study to be
undertaken with efﬁcient use of resources by maximis-
ing the beneﬁts of modern technology including use of
an eCRF and following up patients using record linkage.
The trial design has good external validity by comparing
drugs in a real-world setting and evaluating outcomes in
the patient population most likely to be taking these
drugs.
The Dundee University Research Pharmacy is the ﬁrst
purely research pharmacy in the UK and allows all trial
medication to be posted directly to patients in the UK
and Denmark. This is advantageous for the patient and
their primary care physician, and allows tracking of drug
supply and drug return.
When completed, FAST will help to establish the car-
diovascular safety of febuxostat and allopurinol in a
population with high cardiovascular risk. Efﬁcacy end-
points will also help to deﬁne the role of febuxostat in
the management of patients with gout.
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